Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inovio Pharmaceuticals, Inc.
  6. Summary
    INO   US45773H2013

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
2.070 USD   +9.52%
07/01INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
06/27INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PR
06/24INOVIO PHARMACEUTICALS, INC.(NASDAQGS : INO) added to Russell 3000E Value Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
1.82(c) 1.79(c) 1.73(c) 1.89(c) 2.07 Last
5 567 759 6 150 239 5 739 539 6 026 868 8 077 022 Volume
-6.67% -1.65% -3.35% +9.25% +9.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,81 M - -
Net income 2022 -263 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,77x
Yield 2022 -
Sales 2023 23,9 M - -
Net income 2023 -245 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,11x
Yield 2023 -
Capitalization 433 M 433 M -
Capi. / Sales 2022 239x
Capi. / Sales 2023 18,1x
Nbr of Employees 317
Free-Float 98,3%
More Financials
Company
Inovio Pharmaceuticals, Inc. (INOVIO) is a biotechnology company. The Company is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely... 
Read more
More about the company
Ratings of Inovio Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about INOVIO PHARMACEUTICALS, INC.
07/01INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
06/27INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PR
06/24INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell 3000E Value Index
CI
06/24INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell Microcap Value Index
CI
06/24INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell 3000E Index
CI
06/24INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell Microcap Index
CI
05/27Inovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i..
MT
05/27INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R..
CI
05/25Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
AQ
05/23INOVIO to Present at Jefferies 2022 Healthcare Conference
PR
05/17INOVIO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of Ma..
AQ
05/11Oppenheimer Downgrades Inovio Pharmaceuticals to Perform From Outperform, Removes $30 P..
MT
05/10Inovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO
RE
05/10INOVIO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Change in Di..
AQ
05/10INOVIO : Q1 Earnings Snapshot
AQ
More news
News in other languages on INOVIO PHARMACEUTICALS, INC.
05/27Inovio Pharmaceuticals affirme que la thérapie combinée contre le cancer du cerveau a p..
05/27INOVIO annonce des résultats de survie pour l'INO-5401 + INO-9012 en association avec L..
05/10Earnings Flash (INO) INOVIO PHARMACEUTICALS annonce un chiffre d'affaires de 199,1 mill..
05/10INOVIO annonce des changements au sein de son conseil d'administration
05/10INOVIO annonce des changements de direction
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 2,07 $
Average target price 5,00 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
Jacqueline E. Shea President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Jeffrey Skolnik Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-62.12%433
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-7.58%19 151